WAVE LIFE SCIENCES LTD. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On September 22, 2020, Wave Life Sciences Ltd. (the "Company") issued a press release announcing the commencement of an underwritten public offering of its ordinary shares (the "Offering"). In connection with the Offering, the Company also announced its intention to grant the underwriters an option for a period of up to 30 days to purchase up to an additional 15% of the number of ordinary shares sold in the Offering on the same terms and conditions. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On September 22, 2020, the Company filed with the Securities and Exchange Commission ("SEC") a preliminary prospectus supplement (the "Preliminary Prospectus Supplement") to its effective shelf registration statement on Form S-3, as amended (File No. 333-231382), pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the "Securities Act"), relating to the Offering. The Preliminary Prospectus Supplement contains an updated summary description of the Company's business in the section entitled "Prospectus Supplement Summary," which is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained in Exhibit 99.2 updates and supersedes the information provided in the Company's previous periodic filings with the SEC in order to reflect recent business developments.

This Current Report on Form 8-K, including the exhibits hereto, shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits



Exhibit
  No.                                    Description

99.1          Press release dated September 22, 2020, announcing a proposed
            offering of ordinary shares

99.2          "Prospectus Supplement Summary" of Wave Life Sciences Ltd.'s
            Preliminary Prospectus Supplement dated September 22, 2020 to the
            Registration Statement on Form S-3, as amended (File No. 333- 231382)


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses